<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01611610</url>
  </required_header>
  <id_info>
    <org_study_id>SMA Europe</org_study_id>
    <nct_id>NCT01611610</nct_id>
  </id_info>
  <brief_title>Clinical Assessment of Spinal Muscular Atrophy Type II and III (SMA Europe)</brief_title>
  <official_title>Clinical Assessment of Spinal Muscular Atrophy Type II and III</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Myologie, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Myologie, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this project is to establish a network of clinical teams including the major&#xD;
      neuromuscular centers in Europe.&#xD;
&#xD;
      We plan to work together to find the best common outcome measures for the following&#xD;
      multicenter therapeutic trials.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      16 patients (6 ambulant and 10 non ambulant), affected by type II and type III SMA will be&#xD;
      enrolled and assessed at baseline and 6 and 12 months later. Non ambulant patients will be&#xD;
      assessed using the modified version of the Hammersmith Motor Functional Scale while ambulant&#xD;
      patients will be assessed using the extended module of the Hammersmith Motor Functional Scale&#xD;
      and timed items, the 6 minute walk and a step activity monitor. All patients will also be&#xD;
      assessed using the Motor Function Measure (MFM), that covers the whole range of activities&#xD;
      for both ambulant and non ambulant patients. All measures will undergo a process of&#xD;
      validation including inter observer reliability. This information will be most valuable for&#xD;
      any future trial and will make the groups involved ready to participate to future&#xD;
      collaborative studies saving a lot of time on the preliminary aspects (validation,&#xD;
      reliability, training) that will be fulfilled by the present study. The study will also&#xD;
      provide natural history data for a 12 month period on patients with SMA II and III.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in total score of Motor Function Measure at one year</measure>
    <time_frame>at baseline and one year after</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of Pediatric Quality of Life Inventory Score at one year</measure>
    <time_frame>at baseline and one year after</time_frame>
    <description>Pediatric Quality of Life Inventory - neuromuscular module</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Spinal Muscular Atrophy</condition>
  <arm_group>
    <arm_group_label>Ambulant SMA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-ambulant SMA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Functional tests</intervention_name>
    <description>The ambulant patients will perform&#xD;
MFM (20 items)&#xD;
Hammersmith modified module - MHMFS&#xD;
Timed tests (time to rise from the floor,...)&#xD;
6 minute walk test&#xD;
PedsQL - neuromuscular module</description>
    <arm_group_label>Ambulant SMA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Functional tests</intervention_name>
    <description>The non-ambulant patients will perform:&#xD;
MFM (20 items)&#xD;
Hammersmith modified module - MHMFS&#xD;
Upper Limb Functional Items&#xD;
Egen Klassifikation 2 questionnaire - EK2&#xD;
PedsQL questionnaire - neuromuscular module</description>
    <arm_group_label>Non-ambulant SMA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for ambulant patients:&#xD;
&#xD;
          -  age between 30 months and 24 years&#xD;
&#xD;
          -  documented SMA diagnosis by genetic tests; Each should also have the determination of&#xD;
             the SMN2 copy number&#xD;
&#xD;
          -  able to walk 10 meters without support&#xD;
&#xD;
          -  subject who signed an informed consent- subject affiliated to a social security system&#xD;
&#xD;
        Inclusion Criteria non ambulant patients:&#xD;
&#xD;
          -  documented diagnosis of SMA by genetic tests&#xD;
&#xD;
          -  not able to walk 10 meters without support&#xD;
&#xD;
          -  subject affiliated to a social security system&#xD;
&#xD;
          -  subject who signed an informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient who are currently involved in other clinical trials&#xD;
&#xD;
          -  severe intellectual impairment limiting the comprehension of the demanded tasks&#xD;
&#xD;
          -  acute neurologic, inflammatory, infectious, endocrine, orthopedic disease in the month&#xD;
             preceding the inclusion&#xD;
&#xD;
          -  chronic neurologic (besides SMA), inflammatory, infectious, endocrine, orthopedic&#xD;
             disease which are not a natural consequence of SMA&#xD;
&#xD;
          -  spinal surgery scheduled 6 months before or within 12 months after enrollment&#xD;
&#xD;
          -  pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent Servais, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Myologie</affiliation>
  </overall_official>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>May 30, 2012</study_first_submitted>
  <study_first_submitted_qc>June 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2012</study_first_posted>
  <last_update_submitted>March 4, 2014</last_update_submitted>
  <last_update_submitted_qc>March 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>outcome measures</keyword>
  <keyword>spinal muscular atrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
    <mesh_term>Spinal Muscular Atrophies of Childhood</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

